| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
12,643 |
10,199 |
$1.00M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
8,966 |
6,980 |
$461K |
| 99215 |
Prolong outpt/office vis |
952 |
725 |
$88K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
1,337 |
744 |
$86K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
741 |
572 |
$67K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,015 |
668 |
$51K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
3,006 |
1,353 |
$46K |
| 96127 |
|
3,915 |
3,169 |
$43K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,139 |
695 |
$30K |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
1,180 |
902 |
$26K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
590 |
515 |
$22K |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
2,283 |
1,688 |
$18K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
600 |
477 |
$17K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,278 |
829 |
$12K |
| 36415 |
Collection of venous blood by venipuncture |
3,221 |
2,501 |
$8K |
| 99000 |
|
5,697 |
3,101 |
$6K |
| 99385 |
|
56 |
54 |
$6K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
537 |
201 |
$5K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
49 |
32 |
$5K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
855 |
424 |
$4K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
102 |
76 |
$4K |
| 99386 |
|
29 |
27 |
$4K |
| 0011A |
|
66 |
53 |
$2K |
| 81025 |
|
374 |
227 |
$2K |
| 90686 |
|
163 |
157 |
$2K |
| 87631 |
|
167 |
107 |
$2K |
| 81002 |
|
1,313 |
731 |
$2K |
| 0012A |
|
36 |
34 |
$1K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
15 |
14 |
$1K |
| 0002A |
|
28 |
28 |
$1K |
| 0072A |
|
38 |
36 |
$1K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
431 |
223 |
$1K |
| 0004A |
|
27 |
26 |
$1K |
| 0071A |
|
33 |
27 |
$918.00 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
86 |
53 |
$829.83 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
176 |
84 |
$819.46 |
| 0001A |
|
16 |
15 |
$765.00 |
| 93000 |
|
35 |
25 |
$468.38 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
29 |
17 |
$207.39 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
61 |
41 |
$46.95 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
53 |
39 |
$4.06 |
| 36416 |
|
343 |
58 |
$3.16 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
43 |
17 |
$0.67 |
| 91307 |
|
89 |
72 |
$0.00 |
| 90687 |
|
744 |
195 |
$0.00 |
| 91300 |
|
168 |
150 |
$0.00 |
| 96160 |
|
33 |
27 |
$0.00 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
27 |
27 |
$0.00 |